solid tumors
Entity, reached from Hormuz.
- Evidence
- 109 documents · 35 separate publishers
- Standing
- Added automatically from coverage
- Time
- first seen 1 Jan 2026, last seen 9 Oct 2026
- Measured
- 23% of mentions say something specific about it; the rest only name it
- As of
- 10 Oct 2026
Where this comes from
- PR Newswire · 2026-10-07 · AbbVie's Telisotuzumab Adizutecan (Temab-A) Receives Two Breakthrough Therapy Designations From the U.S. FDA for CRC and NSCLC (opens the source in a new tab)
- MedComm (2020) · 2026-10-06 · KRAS Mutations in Cancers: From Undruggable Dilemma to Precision Medicine. (opens the source in a new tab)
- Nature Medicine · 2026-09-29 · Werner helicase inhibitor for advanced microsatellite instability solid tumors: a phase 1 trial (opens the source in a new tab)
- Front Immunol · 2026-09-18 · CD200-CD200R as a myeloid immune checkpoint in solid tumors: mechanisms, context-dependent functions, and therapeutic opportunities. (opens the source in a new tab)
- Nat Med · 2026-09-15 · Oral KRAS G12D inhibitor GFH375 for previously treated advanced solid tumors with KRASG12D mutations: a phase 1 trial. (opens the source in a new tab)
- Crit Rev Oncol Hematol · 2026-09-13 · Targeting intracellular immune regulatory molecules for cancer immunotherapy in solid tumors. (opens the source in a new tab)
- Annals of Oncology · 2026-09-13 · Corrigendum to “925MO First-in-human phase I/Ib study of the oral Werner (WRN) helicase inhibitor HRO761 in patients (pts) with microsatellite instability-high (MSI-… (opens the source in a new tab)
- Frontiers Precision Oncology · 2026-09-08 · Editorial: Advancing next-generation immunotherapy and biomarker discovery: pioneering the future of treatment strategies in solid tumors (opens the source in a new tab)
- FDA Drug News · 2026-07-15 · [APPROVAL] FDA grants traditional approval to selpercatinib for locally advanced or metastatic RET fusion-positive solid tumors (opens the source in a new tab)
What is claimed about it
Situations it is named in
Who it moves with
- co-mentioned with immunotherapy (53 documents)seen together
- co-mentioned with fda (42 documents)seen together
- co-mentioned with colorectal cancer (37 documents)seen together
- co-mentioned with lung cancer (32 documents)seen together
- co-mentioned with kras (27 documents)seen together
- co-mentioned with t-cell (27 documents)seen together
- co-mentioned with breast cancer (25 documents)seen together
- co-mentioned with clinical trial (25 documents)seen together
- co-mentioned with clinical trials (25 documents)seen together
- co-mentioned with ai (24 documents)seen together